Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Lilly Receives Fourth FDA Approval For ALIMTA(R) (pemetrexed For Injection)
Eli Lilly and Company (NYSE: LLY) announced it received a fourth approval from the U.S. Food and Drug Administration (FDA) for ALIMTA(R) (pemetrexed for injection). The latest approval is for ALIMTA as a maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC), specifically for patients with a nonsquamous histology whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ALIMTA is not indicated for treatment of patients with squamous cell non-small cell lung cancer.
generic viagra online
Gliomas Exploit Immune Cells Of The Brain For Rapid Expansion
Gliomas are among the most common and most malignant brain tumors. These tumors infiltrate normal brain tissue and grow very rapidly. As a result, surgery can never completely remove the tumor. Now, the neurosurgeons Dr. Darko S. Markovic (Helios Klinikum Berlin-Buch) and Dr. Michael Synowitz (Charit̩) as well as Dr. Rainer Glass and Professor Helmut Kettenmann (both Max Delbr̿ck Center for Molecular Medicine, MDC, Berlin-Buch), have been able to show that glioma cells exploit microglia, the immune cells of the brain, for their expansion (PNAS Early Edition)*.
News of the day
Cegedim Dendrite Launches Innovative COUNTERxFEIT DETECT Program
Cegedim Dendrite announced the launch of COUNTERxFEIT DETECT, a new offering that will assist pharmaceutical companies in identifying counterfeit product and determining where it entered their United States supply chains. Cegedim Dendrite is the leading provider of compliance technology solutions and services in the pharmaceutical industry.
Medical Devices

Health Care Ads Leave Washington, Follow Lawmakers Home During Break

Roll Call reports that "several major industry stakeholders" will be "noticeably absent from the advertising airwaves over the July Fourth recess. Though they will continue to keep in touch with Members through meetings and grass roots, AARP, the American Medical Association, America"s Health Insurance Plans, the Federation of American Hospitals and AdvaMed all say they are sitting out this recess when it comes to advertising campaigns." Senate Finance Chairman Max Baucus, D-Mont., and White House aides have "warned that any groups that run ads attacking reform efforts before the bills have been crafted would lose their seats at the bargaining table," but the "advocacy ad floodgates" may "open shortly." Until then, "groups are working in a lower-profile way to get their messages across to Members," such as planning in-district meetings with Members and activating grassroots networks. In addition, "several non-medical industries, including commodities groups and alcoholic beverage companies, which could face a hefty tax increase to help pay for the bill, are expected to advertise against the bill if they"re targeted." But some groups aren"t waiting: "the union-affiliated Health Care for America Now is spending $1.1 million on television ads during this week"s recess, airing spots that encourage voters to press lawmakers to include a public plan in a health care overhaul package" (Ackley, 6/29). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009